logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Stocks > HK Stock

DYNAM JAPAN (06889) spent approximately 457,800 Hong Kong dollars to repurchase 132,400 shares on March 31st.

date
16:52 31/03/2026
avatar
GMT Eight
DYNAM JAPAN (06889) announced on March 31, 2026, the repurchase of approximately 132,400 shares at a cost of about 457,800 Hong Kong dollars.
DYNAM JAPAN (06889) announced that it has spent approximately 457,800 Hong Kong dollars to repurchase 132,400 shares on March 31, 2026.
Related Articles
HK Stock
MICROTECH MED-B(02235) invested 641,000 Hong Kong dollars on March 31 to repurchase 88,000 shares.
HK Stock
Shanghai Fosun Pharmaceutical (02196): FXB0871 approved for clinical trials in locally advanced or metastatic solid tumors.
HK Stock
CHINA PENGFEI (03348) released its annual performance with a net profit attributable to shareholders of 101 million yuan, an increase of 50.02% year-on-year.
MICROTECH MED-B(02235) invested 641,000 Hong Kong dollars on March 31 to repurchase 88,000 shares.
HK Stock
Shanghai Fosun Pharmaceutical (02196): FXB0871 approved for clinical trials in locally advanced or metastatic solid tumors.
HK Stock
CHINA PENGFEI (03348) released its annual performance with a net profit attributable to shareholders of 101 million yuan, an increase of 50.02% year-on-year.
HK Stock
RECOMMEND
Chinese Innovative Drug Assets Attract Major Foreign Acquisition, Cooperation Models Diversify
Chinese Innovative Drug Assets Attract Major Foreign Acquisition, Cooperation Models Diversify
icon
26/03/2026
Four Giants Subscribe As Memory Manufacturer Confirms TWD 78.718 Billion Private Placement For Capacity Expansion
Four Giants Subscribe As Memory Manufacturer Confirms TWD 78.718 Billion Private Placement For Capacity Expansion
icon
26/03/2026
Year‑On‑Year Surge Exceeding 500%: Hong Kong IPOs Top HKD 100 Billion This Year
Year‑On‑Year Surge Exceeding 500%: Hong Kong IPOs Top HKD 100 Billion This Year
icon
26/03/2026
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2026 GMT EIGHT Holdings. All Rights Reserved.